Video

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

Author(s):

Jae Park, MD, Hematologic Oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact that disease burden plays on how adult patients with relapsed precursor B acute lymphoblastic leukemia (B-ALL) respond to cd19-targeted CAR modified T-cells.

Heavily pretreated B-ALL patients have demonstrated a remarkable response rate of 80% with cd19-targeted CAR modified T-cells, says Park. Disease burden does not impact how well the CAR-T cells work.

However, the side effects of CAR T- cells do differ depending on disease burden. The more disease a patient has, the more likely they are to experience toxicities, says Park.

The role of a bone marrow transplant for patients that have received CAR-T cells is also being investigated, says Park.

While the results are not definitive, researchers have found that patients with either low or high disease burden who have receive CAR-T cells and achieved a good remission do not appear to benefit form a bone marrow transplant, says Park.

<<<

View more from the 2016 EHA Congress

Related Videos
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Francine Foss, MD